Maximum Dose of Levosulpiride
The maximum recommended dose of levosulpiride is 75 mg per day, administered as 25 mg three times daily.
Dosing Recommendation
Based on the British Society of Gastroenterology 2022 guidelines for functional dyspepsia, levosulpiride is recommended at 25 mg three times daily (total 75 mg/day) as a second-line treatment 1. This represents the standard maximum dose supported by guideline-level evidence.
Supporting Evidence
The 75 mg/day dosing regimen (25 mg TID) is consistently validated across multiple clinical contexts:
Functional dyspepsia: The BSG guidelines specifically recommend levosulpiride 25 mg three times daily as second-line therapy, noting it should be used with careful patient counseling about rationale and side effects 1
Clinical trial data: A large prospective study of 342 patients with dysmotility-like functional dyspepsia found that 66.4% of patients were effectively treated with 75 mg/day, while 33.6% received 50 mg/day 2. The 75 mg/day dose showed excellent efficacy with acceptable tolerability.
Pharmacokinetic studies: Research in healthy volunteers demonstrated that levosulpiride at 75 mg/day (25 mg TID) reaches steady state by day 4 of multiple dosing 3. However, this study also revealed that more than half of subjects (54.8%) experienced adverse events including constipation, diarrhea, drowsiness, skin rash, and extrapyramidal reactions, indicating the importance of not exceeding this maximum dose.
Important Safety Considerations
Do not exceed 75 mg/day due to:
- High incidence of adverse effects at this dose level, particularly extrapyramidal reactions and galactorrhea 3, 2
- Dopamine D2 receptor blockade effects that increase with higher doses
- The drug's classification as an antipsychotic requiring careful patient counseling 1
Clinical Context
While some studies have explored doses up to 100 mg in research settings 3, the clinically recommended maximum remains 75 mg/day divided into three doses. This dosing provides optimal balance between therapeutic efficacy for gastric motility disorders and acceptable tolerability.